Roberto Gomeni, Carla D’Angeli and Alan Bye
Forecast the minimal effective dose in man using receptor occupancy evaluated in preclinical PET experiments, Clinical Trial Simulation and Dose-to-Event probabilistic model
|
CHARLES Bruce (1,2), CHUAN Francine (1), BOYLE Rhonda (3), RASIAH Rohan (4)
Population Pharmacokinetics Of Intravenous Magnesium Sulphate In Preeclamptic Patients
|
Chao Chen and Yin Yin
Simulation-Revealed Bias In Dose-Response Relationships Obtained From Titration Trials
|
Joga Gobburu(1) and John Lawrence(2)
Estimation of Exact Significance Levels during Nonlinear Mixed Effects Model Building: Some Inferences
|
In-Sun Nam, Leon Aarons, Feiko ter Kuile, Nick White
A Bayesian analysis of halofantrine pharmacokinetics in malaria patients
|
F. Ezzet, G. Krishna, D. Wexler, P. Statkevich, T. Kosoglou, V. Batra
Assessing the Magnitude of Enterohepatic Recirculation of Ezetimibe using a Population Pharmacokinetic Model
|
I.Meineke
Pharmacokinetics of morphine in CSF- Modelling a kinetically invisible distributional space.
|
Julie A Simpson 1,2,3; Leon Aarons 4; William E Collins 5; Geoffrey M Jeffrey 5; Nicholas J White 1,2;
The natural progression of P.falciparum malaria:- Investigation of a historical cohort of syphilis patients treated with malariatherapy.
|
Gordon Graham
Bayesian Optimal Design for Pharmacokinetic/Pharmacodynamic Fixed Effect Models
|
Fotteler B., Weber C. and Steimer JL.
Hot Glucose "Minimal Model" Analysis to Investigate the Pharmacodynamics of an Insulin Sensitiser in Early Drug Development
|
Timothy Goggin1,2Philippe Jacqmin4, Ronald Gieschke1,3, Goonaseelan (Colin) Pillai1,2, Eric Snoeck4, Pascal Girard4, Jean-Louis Steimer1,3.
Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug.
|
Gordon Graham and Leon Aarons
Bayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models
|
L. Aarons, M. Karlsson, F. Mentré, A.V. Peer, F. Rombout, H. Schaefer, J.-L. Steimer, I. Trocóniz
The role of modelling and simulation in the clinical development of anti-cancer agents
|
C. Csajka, T. Buclin, K. Fattinger°, H.R. Brunner,J. Biollaz
Population PK-PD Modelling of Angiotensin II Receptor Antagonists (A2RA) as a Pharmaceutical Class
|
Min Zhu, Vijay Batra and Farkad Ezzet
An Indirect Response Model for the Characterization of Clinical Responses of Interferon alpha-2b Using NONMEM
|
Philip Lowe Ph.D
On mechanism based PK/PD modelling for direct drug-ligand binding systems
|
Fredrik Jonsson
Physiologically based pharmacokinetic modeling in risk assessment -Development of Bayesian population methods
|
Funaki Tomoo, Shiomi Mari
Zero-order infusion model for mixed-effects modeling function - NLME
|
S. Jönsson* and M.O. Karlsson
Factors Influencing The Choice Of Individualised Dosing Strategies Based On Plasma Concentration, Therapeutic Effect Or Utility
|
J. DeJongh1/2, D. Eckland3, R. Heine4 and M. Danhof2.
Population Modelling Of Type 2 Diabetes Mellitus Disease Progression And Treatment With Pioglitazone (Actos)
|
Mercier C(1), Vassal G(2), Tranchand B(1), Sicard E(2), Santos A(2), Vernillet L(3), Pein F(2), Doz F(4), Frappaz D(1), Germa MC(5), Ardiet CJ(1)
Pharmacokinetics of CPT11 and its main metabolites, SN-38, SN-38G, APC, NPC
|
E. Jacqz-Aigrain*, T. Debillon, P. Daoud, C. Boitras, I. Hamon, I. Rayet, M.Popon*, F. Mentré**
Population pharmacokinetics of nalbuphine in neonates
|
Nguyen Quyen T. X.(2), Petricoul O.(1), Cerutti B.(2), Maislich L. (2), Loumaye E.(2), Munafo A.(2)
Population Pharmacokinetic/Pharmacodynamic modelling of Ovidrel in HIV-related male hypogonadotropic hypogonadism
|
Wählby Ulrika*, Bouw René, Jonsson E. Niclas and Karlsson Mats O.
Nominal versus actual significance levels for the statistical model in NONMEM
|
Sophie Glatt (1), Quyen T. X. Nguyen (2); Arnaud Ythier (2) & Alain Munafo (2)
The population pharmacokinetics of Onercept in healthy subjects
|
Retout Sylvie & Mentré France
Further developments of the Fisher information matrix for the evaluation of population pharmacokinetic designs
|
Petricoul O.(1), Nguyen Q.T.X.(2), Decosterd G.(2), Loumaye E.(2), Munafo A.(2)
Population Pharmacokinetic/Pharmacodynamic modelling of Antide in patients undergoing stimulation of multiple follicular development for assisted reproductive technology with recombinant human Follicle Stimulating Hormone
|
Gieschke Ronald1,3, Pillai Goonaseelan (Colin)1,2, Goggin Timothy1,2, Jacqmin Philippe4, Snoeck Eric4, Girard Pascal4, Steimer Jean-Louis1,3
Population PD and Clinical Trial Simulation: Investigating Oral Dosing Regimens for a new Bisphosphonate Drug for Treatment of Osteoporosis
|
Pillai Goonaseelan (Colin)1,2, Gieschke Ronald1,3, Goggin Timothy1,2, Steimer Jean-Louis1,3
Population Pharmacokinetics of Ibandronate in Caucasian and Japanese Post-Menopausal Women.
|
Xie, Rujia1, Mathijssen, Ron H. J.2, Sparreboom, Alex2 and Karlsson, Mats O.1
Clinical Pharmacokintics of Irinotecan (CPT-11) and Its Metabolites
|
Pillai Goonaseelan (Colin)1,2, Gieschke Ronald1,3, Goggin Timothy1,2, Steimer Jean-Louis1,3
A Population Pharmacokinetic-Pharmacodynamic Model for Ibandronate in Japanese Post-Menopausal Osteoporotic Women.
|
D. P de Alwis1, S. Callies2, J G Wright1, I Pouliquen1 and L Aarons2
A population pharmacokinetic model for doxorubucin in the presence of a novel P-gp Modulator, LY335979
|
MERLÉ Y. (1) and TOD M. (2)
Impact Of Model Misspecifications On Optimal Design And Hyperparameter Estimation In Population Pharmacokinetics
|
Vincent Duval and Mats O. Karlsson
Influence of LOQ on the pharmacokinetics parameters after an IV bolus dose
|
Levasseur L., Byrd J., Binet J-L., Bron D., Flinn I., Johnson S., Petric R., Déglise-Favre A., Suarez J-R., Grever M.
Population Pharmacokinetics of a 24-hr Infusion of HMR1275 in Chronic Lymphocytic Leukemia Patients
|
LAPORTE Silvy (1), GIRARD Pascal (2) and MISMETTI Patrick (1), for the OSAP Study Group.
Indirect Pharmacodynamic Model With Two Different Markers Of Two Oral Anticoagulants In Patients
|
Brunhild Schiltmeyer1,2, Georg Hempel1,2, Matthias Schwab3, Thomas Klingebiel4 and Joachim Boos2
Population Pharmacokinetics of Oral Busulfan in Children
|
Diot Annabelle (1), Mallet Alain (1) & Bruno René (2)
Adaptation of Gauss Hermite Quadrature to Estimate Population Parameters in Mixed Models: Application to the Detection of Subpopulations
|
L. Banken, J.-L. Steimer, F. Hemmings, H. Wiltshire
Mixed-effects modelling of the time-course of total and unbound plasma concentration for the anti rheumatoid arthritis agent Ro 32-3555
|
Piotrovsky, Vladimir and Van Peer, Achiel
A generic dynamic mixed-effects model for longitudinal dose-response data
|
Martín,J.D.(1), Soria,E.(1), Camps,G.(1), Serrano,A.J.(1), Pérez,J.J.(2), Jiménez,N.V.(2).
Erythropoietin Dosage Individualisation In Anemic Patients With Chronic Renal Failure.
|
Jakob Ribbing and E. Niclas Jonsson
Cross Model Validation As A Tool For Population Pharmacokinetic/Pharmacodynamic Covariate Model Building
|
Serrano,A.J.(1), Martín,J.D.(1), Pérez,J.J (2), Camps,G.(1), Soria,E.(1), Jiménez,N.V.(2).
An Example Of A Neural Network Like A Pharmacokinetic/Pharmacodynamic Model.
|
Camps-i-Valls, G.1; Porta-Oltra, B.2; Pérez-Ruixo, J. J.2; Soria-Olivas, E.1; Martín-Guerrero, J. D.1; Jiménez-Torres, N. V.2,3
Comparative study of NONMEM and Neural Networks for Cyclosporine Dosage Prediction in Renal Allograft Recipients
|
Soares, M (1)(3), Paixao, P (2)(3), Pereira, L M.(2)(3), Barros, C (2), Cabrita J (2)
Populational phamarmacokinetic of cyclosporin in renal transplantation
|
1,3Llopis MC; 1Pérez-Ruixo JJ; 3Casabó VG; 4Boddy A ; 2Almenar D; 1,3Jiménez NV.
Population Pharmacokinetic Model For Cyclophosphamide Autoinduction In Breast Cancer Patients
|
Kozlowski KH., Idzik M., Milewska-Bobula B., Dunin-Wasowicz D., Lyson-Wojciechowska G.
Population Pharmacokinetics of Gancyclovir Applicated in Newborns and Infants with Congenital Symptomatic Cytomegaly
|
Sandström M, Lindman H, Bergh J and Karlsson M O.
PK/PD of the Epirubicin-Docetaxel therapy in breast cancer patients.
|
Zingmark, Per-Henrik* Edenius, Charlotte* and Karlsson Mats O**
Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis (MS)
|
E. N. Jonsson, F. Macintyre, I. James, W. Wild and S. Marshall
A mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients
|
Reif S. (1), Kloft C. (1), Jetter A. (2), Fuhr U. (2), Siegert W. (3), McLeod H. (4), Schunack W. (1), Jaehde U. (1,5)
Population pharmacokinetic parameter estimation to assess the impact of dose on etoposide pharmacokinetics
|
Rapado, Javier., Fabregas, Neus., Valero, Ricard., Carrero, Enrique., Gambús, Pedro., Trocóniz, Iñaki
Pharmacodynamic modelling of sedation and respiratory effects of propofol in Parkinson disease patients undergoing functional stereotactic surgery
|
Lewis B Sheiner
Dealing With Missing Data in Longitudinal Studies Through Modeling
|
Xuejun Chen1, Ekaterina Gibiansky2, Suresh Mallikaarjun1,
Population Pharmacokinetic Analysis Of Aripiprazole
|
NGUYEN L., VARIOL P., PUOZZO C.
Population pharmacokinetic scaling up from animal to patient of a novel anti-cancer drug (vinflunine): a tool to predict the maximum tolerated dose in early clinical trial.
|
Dave Lunn
Graphical Models and Missing Data
|
NHG Holford1, S Bååthe 2, Mats Karlsson2
Auckland Bones and Summer Sun
|
Philippe Jacqmin1, Ronald Gieschke2,4, Paul Jordan2,4, Jean-Louis Steimer2,4, Timothy Goggin2,3, Goonaseelan (Colin) Pillai2,3, Eric Snoeck1, Pascal Girard1.
Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model
|
J.G.Wright
Forward selection and other recipes for disaster
|
A. Rostami-Hodjegan, A. Tooley, G.T.Tucker
Incorporating Interindividual Variability into "In Vitro - In Vivo Extrapolation"
|
Karlsson Mats, Jonsson Niclas and Zingmark Per-Henrik
Models for sedation scores in acute stroke patients
|
Rik C. Schoemaker, Madelon M. Buijs1, Hanno Pijl1 and Adam F. Cohen
Integrated mathematical modeling of lipolysis
|
Kimko, Hui C.
Iron kinetics: when drug loss by sampling is critical in data analysis
|
Ivan Nestorov
Sensitivity Analysis of PBPK and PK/PD Models
|
Joe Schafer
Multiple Imputation for Missing-Data Problems
|
Paolo Vicini
Integrated system models to understand disease status, progression and therapy: case studies
|
Leary R, Jelliffe R, Schumitzky A, and Van Guilder M
New Advances in Nonparametric PK/PD Population Modeling
|
Van Guilder M(1), Leary R(2), Schumitzky A(1), and Jelliffe R(1)
A Bootstrap Algorithm For Confidence Limits For Nonparametric Population Models
|
Botnen A(1), Wang X(1), Jelliffe R(1), Thomas M(2), and Hoem N(1)
Population Pharmacokinetic / Dynamic Modeling Via The World Wide Web
|
Hoem, N.O. and Jelliffe, R
An Npem Population Analysis Of Ciclosporine - Modelling Oral Drug Absorption As A Time-Dependent Function
|
J-B. FAU, C. DUBRUC, S. CHAUFOUR, P. ROSENZWEIG, P. SCHEINMANN* and F. MENTRE**
Population Pharmacokinetic Analysis Of Mizolastine In Children 2 To 5 Years Old Using NONMEM
|
Ana Martín Suárez (1,4), John C Lukas (1), Rosario Calvo (2), M Paz Valverde (3), M Victoria Calvo (3), José M Lanao (4) and Alfonso Domínguez-Gil Hurlé (3,4)
Population time dependent pharmacokinetics of cyclosporine in renal transplant patients
|
Lars Lindbom and E. Niclas Jonsson
High-Performance Computing In PK/PD – Parallel Execution Of NONMEM Runs On A Linux Cluster
|
Lena E. Friberg and Mats O. Karlsson
A semi-physiological model for the pharmacodynamic interaction on leukocytes after 5-fluorouracil and epirubicin administration
|
S.Gisbert(1), V.Cosson(1), E.Fuseau(1) T. Senderovitz(2)
PK/PD Modelling O of Antidiuretic Effect of Desmopressin (dDAVP) After Oral Administration in Elderly Men in a Phase II Study Using NONMEM
|
C. Laveille, C. Christin-Maitre*, C. Varin, Y. Tsouderos, and R. Jochemsen.
Hormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of Estradiol (E2) in postmenopausal women
|
Ferdie Rombout
LOQ, a relic of the past?
|
